FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2398323629> ?p ?o ?g. }

• W2398323629 endingPage "91" @default.
• W2398323629 startingPage "89" @default.
• W2398323629 abstract "The clinical development of the recombinant alpha interferons represents a prototype for the clinical development of biological compounds. Their testing raises fundamental questions concerning phase I objectives and strategies for biologicals, eg, study design in an immune model v a cytotoxic model. However, with over 5,000 patients treated with these compounds, some general principles have emerged. There is a suggestion of dose-response relationships, and a clearer picture of schedule dependence. The extent of tumor burden and identification of sensitive subtypes of patients also appear to be critical factors in evaluating the true potential activity of biological compounds. The toxicity profile of the alpha interferons is unusual. Fever and flu-like symptoms occur almost universally in all doses and schedules, and are usually dose-limiting. Somnolence and other CNS effects occur in a small percentage of patients. Hematologic toxicity occurs but is minimal at lower doses and is noncumulative and rapidly reversible at all doses. Gastrointestinal toxicity is mild. No other unusual or unexpected toxicities have been reported, and early reports of cardiovascular toxicity have not been confirmed in large trials. The use of these pioneer recombinant DNA products raised concerns about the potential production of antibodies and serum-neutralizing factors. Reports with small patient numbers confirmed the occasional development of serum-neutralizing activity to some alpha interferons, which may coincide with a loss of detectable serum interferon and loss of clinical activity. A large study with interferon alfa-2b (Intron A) has reported a low overall incidence of neutralizing activity (2.5%) and no association with loss of clinical activity. The significance of the neutralizing activity and the reasons for an apparently higher incidence of this phenomenon with other alpha interferon preparations remain to be determined. The full role of alpha interferon by itself or in combination with other available therapies will be resolved in coming years. Efficacy data available to date and phase I combination studies are reviewed." @default.
• W2398323629 created "2016-06-24" @default.
• W2398323629 creator A5050411909 @default.
• W2398323629 date "1986-09-01" @default.
• W2398323629 modified "2023-09-23" @default.
• W2398323629 title "Brief overview of combination chemotherapy in non-small-cell lung cancer." @default.
• W2398323629 cites W131666574 @default.
• W2398323629 cites W1595896331 @default.
• W2398323629 cites W1598648478 @default.
• W2398323629 cites W1763977733 @default.
• W2398323629 cites W1875354643 @default.
• W2398323629 cites W1973409404 @default.
• W2398323629 cites W1975978239 @default.
• W2398323629 cites W1980103613 @default.
• W2398323629 cites W1982430046 @default.
• W2398323629 cites W2012448707 @default.
• W2398323629 cites W2027898486 @default.
• W2398323629 cites W2037650318 @default.
• W2398323629 cites W2038570077 @default.
• W2398323629 cites W2052677652 @default.
• W2398323629 cites W2054687940 @default.
• W2398323629 cites W2062717712 @default.
• W2398323629 cites W2066957976 @default.
• W2398323629 cites W2067903799 @default.
• W2398323629 cites W2068049913 @default.
• W2398323629 cites W2075607397 @default.
• W2398323629 cites W2091703047 @default.
• W2398323629 cites W2128394628 @default.
• W2398323629 cites W2167805334 @default.
• W2398323629 cites W2179466343 @default.
• W2398323629 cites W2188971903 @default.
• W2398323629 cites W2261294575 @default.
• W2398323629 cites W2307147645 @default.
• W2398323629 cites W2337803710 @default.
• W2398323629 cites W2339932366 @default.
• W2398323629 cites W2401071174 @default.
• W2398323629 cites W2409391990 @default.
• W2398323629 cites W2411553622 @default.
• W2398323629 cites W2419617426 @default.
• W2398323629 cites W2462276446 @default.
• W2398323629 cites W32671482 @default.
• W2398323629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3532338" @default.
• W2398323629 hasPublicationYear "1986" @default.
• W2398323629 type Work @default.
• W2398323629 sameAs 2398323629 @default.
• W2398323629 citedByCount "27" @default.
• W2398323629 countsByYear W23983236292013 @default.
• W2398323629 crossrefType "journal-article" @default.
• W2398323629 hasAuthorship W2398323629A5050411909 @default.
• W2398323629 hasConcept C104317684 @default.
• W2398323629 hasConcept C126322002 @default.
• W2398323629 hasConcept C143998085 @default.
• W2398323629 hasConcept C159654299 @default.
• W2398323629 hasConcept C185592680 @default.
• W2398323629 hasConcept C203014093 @default.
• W2398323629 hasConcept C2776178377 @default.
• W2398323629 hasConcept C2909179924 @default.
• W2398323629 hasConcept C29730261 @default.
• W2398323629 hasConcept C40767141 @default.
• W2398323629 hasConcept C55493867 @default.
• W2398323629 hasConcept C71924100 @default.
• W2398323629 hasConcept C90924648 @default.
• W2398323629 hasConcept C98274493 @default.
• W2398323629 hasConceptScore W2398323629C104317684 @default.
• W2398323629 hasConceptScore W2398323629C126322002 @default.
• W2398323629 hasConceptScore W2398323629C143998085 @default.
• W2398323629 hasConceptScore W2398323629C159654299 @default.
• W2398323629 hasConceptScore W2398323629C185592680 @default.
• W2398323629 hasConceptScore W2398323629C203014093 @default.
• W2398323629 hasConceptScore W2398323629C2776178377 @default.
• W2398323629 hasConceptScore W2398323629C2909179924 @default.
• W2398323629 hasConceptScore W2398323629C29730261 @default.
• W2398323629 hasConceptScore W2398323629C40767141 @default.
• W2398323629 hasConceptScore W2398323629C55493867 @default.
• W2398323629 hasConceptScore W2398323629C71924100 @default.
• W2398323629 hasConceptScore W2398323629C90924648 @default.
• W2398323629 hasConceptScore W2398323629C98274493 @default.
• W2398323629 hasIssue "3 Suppl 3" @default.
• W2398323629 hasLocation W23983236291 @default.
• W2398323629 hasOpenAccess W2398323629 @default.
• W2398323629 hasPrimaryLocation W23983236291 @default.
• W2398323629 hasRelatedWork W2013906813 @default.
• W2398323629 hasRelatedWork W2033100330 @default.
• W2398323629 hasRelatedWork W2285211143 @default.
• W2398323629 hasRelatedWork W2355902919 @default.
• W2398323629 hasRelatedWork W2371666691 @default.
• W2398323629 hasRelatedWork W2378355431 @default.
• W2398323629 hasRelatedWork W2406279120 @default.
• W2398323629 hasRelatedWork W2899084033 @default.
• W2398323629 hasRelatedWork W2981378876 @default.
• W2398323629 hasRelatedWork W3198647362 @default.
• W2398323629 hasVolume "13" @default.
• W2398323629 isParatext "false" @default.
• W2398323629 isRetracted "false" @default.
• W2398323629 magId "2398323629" @default.
• W2398323629 workType "article" @default.